Literature DB >> 27775864

Cardiogenic Shock Predicts Long-term Mortality in Hospital Survivors of STEMI Treated With Primary Percutaneous Coronary Intervention.

Veemal V Hemradj1, Jan Paul Ottervanger1, Arnoud W van 't Hof1, Jan Henk Dambrink1, Marcel Gosselink1, Elvin Kedhi1, Harry Suryapranata1,2.   

Abstract

BACKGROUND: ST-segment elevation myocardial infarction (STEMI) complicated by cardiogenic shock (CS) has a poor prognosis. Recently published data suggested, however, that CS does not affect long-term mortality in hospital survivors of STEMI. We investigated whether this could be confirmed in a larger cohort. HYPOTHESIS: STEMI complicated by CS leads to worse long-term survival.
METHODS: A prospective cohort study was performed in 7412 consecutive patients with STEMI treated by primary percutaneous coronary intervention (angioplasty). The predictive value of CS on long-term mortality was assessed in hospital survivors. Multivariate analysis, adjusting for differences in baseline variables, was performed to assess the independent prognostic value of CS.
RESULTS: Cardiogenic shock was observed in 387 patients (5.2%). The total in-hospital mortality was 254 (3.4%), and mortality was significantly higher in patients with CS (20.0% vs 2.6%; P < 0.001). The 1-year mortality in hospital survivors was 10.3% in patients with CS and 3.9% in patients without CS (P < 0.001). After multivariate analysis, CS was still a significant predictor of long-term mortality in hospital survivors (hazard ratio: 2.6, 95% confidence interval: 1.64-4.01).
CONCLUSIONS: Cardiogenic shock remains a strong predictor of long-term mortality in hospital survivors of STEMI treated by primary percutaneous coronary intervention.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  Acute coronary syndrome; Ischemic heart disease; myocardial infarction

Mesh:

Year:  2016        PMID: 27775864      PMCID: PMC6490725          DOI: 10.1002/clc.22580

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  18 in total

1.  Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock.

Authors:  Anvar Babaev; Paul D Frederick; David J Pasta; Nathan Every; Tina Sichrovsky; Judith S Hochman
Journal:  JAMA       Date:  2005-07-27       Impact factor: 56.272

2.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.

Authors:  Gust H Bardy; Kerry L Lee; Daniel B Mark; Jeanne E Poole; Douglas L Packer; Robin Boineau; Michael Domanski; Charles Troutman; Jill Anderson; George Johnson; Steven E McNulty; Nancy Clapp-Channing; Linda D Davidson-Ray; Elizabeth S Fraulo; Daniel P Fishbein; Richard M Luceri; John H Ip
Journal:  N Engl J Med       Date:  2005-01-20       Impact factor: 91.245

3.  Cardiogenic shock complicating acute myocardial infarction: predictors of death. GUSTO Investigators. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary Arteries.

Authors:  D Hasdai; D R Holmes; R M Califf; T D Thompson; J S Hochman; M Pfisterer; E J Topol
Journal:  Am Heart J       Date:  1999-07       Impact factor: 4.749

4.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC.

Authors:  John J V McMurray; Stamatis Adamopoulos; Stefan D Anker; Angelo Auricchio; Michael Böhm; Kenneth Dickstein; Volkmar Falk; Gerasimos Filippatos; Cândida Fonseca; Miguel Angel Gomez-Sanchez; Tiny Jaarsma; Lars Køber; Gregory Y H Lip; Aldo Pietro Maggioni; Alexander Parkhomenko; Burkert M Pieske; Bogdan A Popescu; Per K Rønnevik; Frans H Rutten; Juerg Schwitter; Petar Seferovic; Janina Stepinska; Pedro T Trindade; Adriaan A Voors; Faiez Zannad; Andreas Zeiher
Journal:  Eur Heart J       Date:  2012-05-19       Impact factor: 29.983

5.  The clinical profile of patients with suspected cardiogenic shock due to predominant left ventricular failure: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries in cardiogenic shocK?

Authors:  V Menon; H White; T LeJemtel; J G Webb; L A Sleeper; J S Hochman
Journal:  J Am Coll Cardiol       Date:  2000-09       Impact factor: 24.094

6.  Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock.

Authors:  J S Hochman; L A Sleeper; J G Webb; T A Sanborn; H D White; J D Talley; C E Buller; A K Jacobs; J N Slater; J Col; S M McKinlay; T H LeJemtel
Journal:  N Engl J Med       Date:  1999-08-26       Impact factor: 91.245

7.  Thirty-year trends (1975 to 2005) in the magnitude of, management of, and hospital death rates associated with cardiogenic shock in patients with acute myocardial infarction: a population-based perspective.

Authors:  Robert J Goldberg; Frederick A Spencer; Joel M Gore; Darleen Lessard; Jorge Yarzebski
Journal:  Circulation       Date:  2009-02-23       Impact factor: 29.690

8.  Early revascularization is associated with improved survival in elderly patients with acute myocardial infarction complicated by cardiogenic shock: a report from the SHOCK Trial Registry.

Authors:  V Dzavik; L A Sleeper; T P Cocke; M Moscucci; J Saucedo; S Hosat; X Jiang; J Slater; T LeJemtel; J S Hochman
Journal:  Eur Heart J       Date:  2003-05       Impact factor: 29.983

9.  Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).

Authors:  K M Fox
Journal:  Lancet       Date:  2003-09-06       Impact factor: 79.321

10.  Intraaortic balloon support for myocardial infarction with cardiogenic shock.

Authors:  Holger Thiele; Uwe Zeymer; Franz-Josef Neumann; Miroslaw Ferenc; Hans-Georg Olbrich; Jörg Hausleiter; Gert Richardt; Marcus Hennersdorf; Klaus Empen; Georg Fuernau; Steffen Desch; Ingo Eitel; Rainer Hambrecht; Jörg Fuhrmann; Michael Böhm; Henning Ebelt; Steffen Schneider; Gerhard Schuler; Karl Werdan
Journal:  N Engl J Med       Date:  2012-08-26       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.